Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
116
resultados
Última actualización
03/08/2025 [06:49:00]
Resultados 50 a 75 de 116
Resumen de: US2025235525A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Resumen de: US2025236645A1
This present disclosure provides RNA expression systems based on sequences from plant viruses, insect viruses, and flaviviruses that eliminate the need for expensive modifications. Methods to express and package an RNA polynucleotide without the need for in vitro transcription and lipid nanoparticles are provided. Also provided are methods to package an RNA polynucleotide using synthetic polyanhydride nanoparticles that are stable at room temperature and suitable for delivery by nasal spray.
Resumen de: US2025236599A1
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
Resumen de: US2025235500A1
Disclosed in the present invention are a new polypeptide for promoting tissue repair, and the use thereof. The new polypeptide can promote the proliferation of human immortalized epidermal cells and the migration of human epidermal fibroblasts at a relatively low concentration, can promote the repair of wounds and ulcers, improves the aesthetic feeling of the skin, has low toxic side effects, has good application prospects, and can be used for preparing a drug and a medical instrument for treating wound surfaces, scalds and ulcers or for preparing an everyday chemical for improving the aesthetic feeling of the skin.
Resumen de: US2025235411A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Resumen de: AU2024207086A1
A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.
Resumen de: AU2025204994A1
Compositions and methods for delivering non-anionic polynucleotide analog cargoes to the cytosolic/nuclear compartment of eukaryotic cells via a synthetic peptide shuttle agent are described herein. The non-anionic polynucleotide analog cargoes may be charge-neutral or cationic, and the synthetic peptide shuttle agent is a peptide comprising an amphipathic alpha-helical motif having both a 5 positively-charged hydrophilic outer face and a hydrophobic outer face, wherein synthetic peptide shuttle agent is not covalently linked, or linked in a cleavable manner under physiological conditions, to the non- anionic polynucleotide analog cargoes. The non-anionic polynucleotide analog cargo may be a charge- neutral or cationic antisense synthetic oligonucleotide (ASO) that hybridizes to an intracellular target RNA for gene expression modification. 10 Compositions and methods for delivering non-anionic polynucleotide analog cargoes to the cytosolic/nuclear compartment of eukaryotic cells via a synthetic peptide shuttle agent are described herein. The non-anionic polynucleotide analog cargoes may be charge-neutral or cationic, and the 5 synthetic peptide shuttle agent is a peptide comprising an amphipathic alpha-helical motif having both a positively-charged hydrophilic outer face and a hydrophobic outer face, wherein synthetic peptide shuttle agent is not covalently linked, or linked in a cleavable manner under physiological conditions, to the non- anionic polynucleotide analog cargoe
Resumen de: AU2023410864A1
The invention provides a composition, e.g., in the form of a powder, comprising chitosan particles. The invention also provides method for treating an oral condition in a patient by administering to the patient a composition of the invention to treat the oral condition. The invention further provides devices suitable for administering the composition.
Resumen de: WO2025153768A1
The disclosure relates to a composition comprising nanoparticles of crystalline apalutamide and polyvinylpyrrolidone/vinyl acetate (PVPVA) and/or hydroxypropyl methyl cellulose (HPMC). The disclosure also relates to a method for producing the composition.
Resumen de: WO2025155926A1
The present technology provides methods of reducing vein graft injury comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the vein to be grafted prior to surgical implantation of the vein graft in a subject. Additionally, the present technology provides methods of improving vein graft health and preventing or treating post-operative restenosis and also provides bioavailable nanoparticles comprising NAD+ and/or NADH and a coating comprising a human cell membrane for use in such methods.
Resumen de: WO2025155929A1
The present technology provides methods of reducing ischemia-reperfusion (IR) injury in a kidney to be transplanted comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the kidney prior to surgical transplantation of the kidney into a subject. Additionally, the present technology provides methods of reducing ischemia-reperfusion (IR) injury to a transplanted kidney in a subject comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the subject after transplantation of the kidney into the subject and also provides bioavailable nanoparticles comprising NAD+ and/or NADH for use in such methods.
Resumen de: WO2025155702A1
Adjuvant compositions, and vaccine compositions utilizing the adjuvant compositions, are described. The adjuvant compositions include a salt-crosslinked TEMPO-oxidized cellulose nanofibril (CNF) hydrogel, and the vaccine compositions further include an antigen or immunogen.
Resumen de: WO2025155087A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles that can deliver nucleic acids, and a lipid nanoparticle preparation method using same. By using the microfluidic device, lipid nanoparticles of a desired size can be prepared by adjusting the molar ratio between compositions and the Reynolds number.
Resumen de: WO2025155269A1
The invention relates to serum containing encapsulated niaouli essential oil. In the preparation of said serum, firstly niaouli essential oil is encapsulated and then the obtained micro/nanoparticles are loaded into the serum carrier system. The serum containing encapsulated niaouli essential oil, which is the subject of the invention, contains olive oil, caprylic/capric triglyceride, cyclopentasiloxane, isopropyl myristate and encapsulated niaoulii essential oil. The serum containing encapsulated niaouli essential oil is used as a new alternative treatment method for eczema treatment.
Resumen de: WO2025153098A1
A pulmonary delivery system containing an ionizable lipid, and a preparation method therefor and the use thereof, which belong to the technical field of biomedicine. The pulmonary delivery system containing an ionizable lipid comprises an ionizable lipid, an auxiliary lipid, and a bioactive substance, and does not contain polymer-lipid conjugates. The pulmonary delivery system containing an ionizable lipid can deliver the bioactive substance to the lungs. The pulmonary delivery system has the characteristics of uniform particle size and high safety, and can efficiently deliver a therapeutic agent to the lungs. Before and after atomization, the particle properties such as the particle size, particle size distribution coefficient, potential, and encapsulation efficiency remain unchanged. The pulmonary delivery system provides a safe and effective solution for the treatment of pulmonary diseases, and has broad application prospects.
Resumen de: WO2025153099A1
The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells, which belongs to the technical field of biomedicine. The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells comprises the step of mixing the prefabricated carrier with a nucleic acid in a solvent to obtain a composition based on the prefabricated carrier. The composition of the prefabricated carrier comprises: an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-conjugated lipid. The prefabricated carrier can be used as a carrier tool for cell and gene therapy.
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: WO2025153095A1
A lipid composition and a preparation method therefor and the use thereof. The lipid composition comprises the following components: an ionizable lipid and an auxiliary lipid, and does not contain a component having a preventive or therapeutic effect. The lipid composition can be used for delivering nucleic acids, macromolecular substances and small molecular substances, has a good stability, can be stored at room temperature for a long time, and can be used as a carrier in multiple fields such as cell and disease treatment and prevention.
Resumen de: WO2025152109A1
A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.
Resumen de: US2025235412A1
A poly(beta-aminoester) polymer of formula (I) or a pharmaceutically salt thereof which comprises one or more zwitterionic polymers. Advantageously, the polymer of the invention shows improved properties when formulated in the form of nanoparticles. Processes for the preparation of the polymer, nanoparticles comprising a polymer of Formula (I) and uses thereof.
Resumen de: US2025235404A1
Disclosed herein are polyethylene glycol (PEG)-lipids, functionalized PEG-lipids, and functionalized PEG-lipids that are conjugated to a binding moiety which can comprise an antibody antigen binding domain. Also disclosed are methods for synthesizing and functionalizing the PEG-lipids. The PEG-lipids are useful components lipid nanoparticles (LNP) used for the delivery of nucleic acids into living cells, in vivo or ex vivo. LNP comprising functionalized PEG-lipids that are conjugated to a binding moiety are useful as targeted LNP for delivering nucleic acids into cells or tissues expressing the ligand of the binding moiety.
Resumen de: US2025235394A1
Nanoparticles for treating a tooth in an oral cavity of a subject are provided. The nanoparticle comprises a biocompatible and biodegradable hydrophilic polymer, a matrix-degrading enzyme, and an anticaries active ingredient present in the nanoparticle at greater than or equal to about 20% by weight. The nanoparticle has a zeta potential between about −10 mV to about +10 mV at a pH of 7. The nanoparticle is capable of selectively accumulating within a biofilm matrix associated with a surface of the tooth in the oral cavity of the subject. Oral care composition and methods of treating a tooth in an oral cavity of a subject with such nanoparticles are also provided.
Resumen de: US2025235405A1
A nanoparticulate composition comprising a core comprising a therapeutically active agent selected from a nucleic acid, protein or peptide packaged within a non-viral drug delivery vehicle is described. The core comprises a low molecular weight stabilizing agent comprising at least one atom or group that is charged in aqueous solution, wherein when the therapeutic agent is negatively charged the charged atom or group is positively charged in aqueous solution and when the therapeutic agent is positively charged the charged atom or group is negatively charged in aqueous solution.
Resumen de: US2025235400A1
The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about −10 mV. Further provided are processes for preparing such nanoemulsions.
Nº publicación: US2025235401A1 24/07/2025
Solicitante:
INSUCAPS LTD [IE]
Insucaps Limited
Resumen de: US2025235401A1
An oil in water nanoemulsion has an oil phase and an aqueous phase and comprises active pharmaceutical ingredient (API), edible oil, denatured plant protein, surfactant, and water, in which the API is contained in the oil phase. The API comprises an RNA molecule or a hydrophobic drug. The oil is high oleic oil. The oil in water nanoemulsion may be combined with a suspension of denatured plant protein and a calcium salt chelating agent to form microparticles or microcapsules comprising the nanoemulsion or the oil droplets of the nanoemulsion encapsulated within a denatured plant protein matrix. The microcapsules can be ingested orally and pass through the stomach to the ileum where the protein matrix breaks down to release the oil droplets containing the API, which is then absorbed.
BOPI
Sede Electrónica
